312 related articles for article (PubMed ID: 8910322)
1. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
2. Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.
Saenko EL; Scandella D; Yakhyaev AV; Greco NJ
J Biol Chem; 1998 Oct; 273(43):27918-26. PubMed ID: 9774404
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa.
Pipe SW; Kaufman RJ
Proc Natl Acad Sci U S A; 1997 Oct; 94(22):11851-6. PubMed ID: 9342326
[TBL] [Abstract][Full Text] [Related]
4. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
[TBL] [Abstract][Full Text] [Related]
5. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
[TBL] [Abstract][Full Text] [Related]
6. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
Scandella D; Gilbert GE; Shima M; Nakai H; Eagleson C; Felch M; Prescott R; Rajalakshmi KJ; Hoyer LW; Saenko E
Blood; 1995 Sep; 86(5):1811-9. PubMed ID: 7544643
[TBL] [Abstract][Full Text] [Related]
7. Role of activation of the coagulation factor VIII in interaction with vWf, phospholipid, and functioning within the factor Xase complex.
Saenko EL; Shima M; Sarafanov AG
Trends Cardiovasc Med; 1999 Oct; 9(7):185-92. PubMed ID: 10881749
[TBL] [Abstract][Full Text] [Related]
8. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
9. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.
Meeks SL; Healey JF; Parker ET; Barrow RT; Lollar P
Blood; 2007 Dec; 110(13):4234-42. PubMed ID: 17848617
[TBL] [Abstract][Full Text] [Related]
10. Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants.
Gale AJ; Radtke KP; Cunningham MA; Chamberlain D; Pellequer JL; Griffin JH
J Thromb Haemost; 2006 Jun; 4(6):1315-22. PubMed ID: 16706977
[TBL] [Abstract][Full Text] [Related]
11. The effect of thrombin on the complex between factor VIII and von Willebrand factor.
Hamer RJ; Koedam JA; Beeser-Visser NH; Sixma JJ
Eur J Biochem; 1987 Sep; 167(2):253-9. PubMed ID: 3113951
[TBL] [Abstract][Full Text] [Related]
12. The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.
Li X; Gabriel DA
Biochemistry; 1997 Sep; 36(35):10760-7. PubMed ID: 9271507
[TBL] [Abstract][Full Text] [Related]
13. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
[TBL] [Abstract][Full Text] [Related]
14. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
15. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
16. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage.
Precup JW; Kline BC; Fass DN
Blood; 1991 May; 77(9):1929-36. PubMed ID: 1902121
[TBL] [Abstract][Full Text] [Related]
17. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.
Jacquemin MG; Desqueper BG; Benhida A; Vander Elst L; Hoylaerts MF; Bakkus M; Thielemans K; Arnout J; Peerlinck K; Gilles JG; Vermylen J; Saint-Remy JM
Blood; 1998 Jul; 92(2):496-506. PubMed ID: 9657749
[TBL] [Abstract][Full Text] [Related]
18. A monoclonal antibody (NMC-VIII/10) to factor VIII light chain recognizing Glu1675-Glu1684 inhibits factor VIII binding to endogenous von Willebrand factor in human umbilical vein endothelial cells.
Shima M; Yoshioka A; Nakajima M; Nakai H; Fukui H
Br J Haematol; 1992 Aug; 81(4):533-8. PubMed ID: 1390241
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
20. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
